<DOC>
	<DOCNO>NCT02554136</DOCNO>
	<brief_summary>The investigator investigate potential pharmacokinetic drug-drug interaction HGP0918 HGP0816 healthy adult subject receive HGP0918 alone , HGP0816 alone , together 3 period repeatedly</brief_summary>
	<brief_title>Evaluating Pharmacokinetic Drug Interaction Between HGP0918 HGP0816</brief_title>
	<detailed_description />
	<criteria>Subjects ability comprehend objective , content study property study drug participate trial willingness sign inform consent write Healthy male volunteer , age 19 55 year . The result Body Mass Index ( BMI ) less 18.5 kg/m2 , 27.0 kg/m2 Presence medical history concurrent disease may interfere treatment safety assessment completion clinical study , include clinically significant disorder digestive system , neuropsychiatric system , endocrine system , liver , cardiovascular system Someone decline liver function Liver enzyme ( AST , ALT total bilirubin ) level exceed one half time normal upper range Somenone decline kidney function eGFR &lt; 60mL/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>